LB Pharmaceuticals grants 195,000 options to chief commercial officer

LB Pharmaceuticals reported that its chief commercial officer received an employee stock option grant covering 195,000 shares of common stock.

Rhea-AI Filing Summary

LB Pharmaceuticals reported that its chief commercial officer received an employee stock option grant covering 195,000 shares of common stock. The option, dated 12/10/2025, has an exercise price of $21.36 per share and expires on 12/09/2035.

One fourth of the shares vest on 11/10/2026, with the remaining shares vesting in 36 equal monthly installments on the last calendar day of each month starting 12/31/2026, subject to the officer’s continuous service. Following this grant, the officer beneficially owns 195,000 stock options, held directly.

Insider Trade Summary

Grant/Award: 195,000 shares

Grant/Award 1 txn

Insider Pai Panandiker Kaya Kamlesh

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	195,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 195,000 contracts (Direct)

Footnotes (1)

1. F1. One fourth (1/4) of the shares subject to the option award shall vest on November 10, 2026 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments on the last calendar day of each month with the first monthly installment occurring on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LB Pharmaceuticals (LBRX) disclose?

LB Pharmaceuticals reported an employee stock option grant to its chief commercial officer covering 195,000 shares of common stock at an exercise price of $21.36 per share.

When were the LB Pharmaceuticals employee stock options granted and when do they expire?

The employee stock options were granted on 12/10/2025 and have an expiration date of 12/09/2035.

How do the 195,000 LB Pharmaceuticals (LBRX) options vest?

According to the vesting schedule, one fourth of the shares vest on 11/10/2026, and the remaining shares vest in 36 equal monthly installments on the last calendar day of each month beginning 12/31/2026, subject to continuous service.

How many derivative securities does the officer beneficially own after this LB Pharmaceuticals grant?

After the reported transaction, the officer beneficially owns 195,000 employee stock options, as shown in the derivative securities table.

Is the reported LB Pharmaceuticals ownership direct or indirect?

The Form 4 indicates an ownership form of Direct (D) for the 195,000 employee stock options.

What is the underlying security for the LB Pharmaceuticals employee stock options?

The underlying security for the employee stock options is common stock, with an underlying amount of 195,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/11/2025 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pai Panandiker Kaya Kamlesh

(Last) (First) (Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK NY 10119

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$21.36	12/10/2025		A		195,000		(1)	12/09/2035	Common Stock	195,000	$0	195,000	D

Explanation of Responses:

1. One fourth (1/4) of the shares subject to the option award shall vest on November 10, 2026 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments on the last calendar day of each month with the first monthly installment occurring on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Marc Panoff, Attorney-in-Fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.